38 results on '"Friberg, Lena E."'
Search Results
2. Physiologically-based pharmacokinetic models versus allometric scaling for prediction of tyrosine-kinase inhibitor exposure from adults to children
3. Quantifying combined effects of colistin and ciprofloxacin against Escherichia coli in an in silico pharmacokinetic-pharmacodynamic model
4. Model-Informed Precision Dosing to Reduce Vincristine-Induced Peripheral Neuropathy in Pediatric Patients: A Pharmacokinetic and Pharmacodynamic Modeling and Simulation Analysis
5. Publisher Correction: Anti-cancer treatment schedule optimization based on tumor dynamics modelling incorporating evolving resistance
6. Anti-cancer treatment schedule optimization based on tumor dynamics modelling incorporating evolving resistance
7. Population Pharmacokinetics of Flucloxacillin In Bone and Soft Tissue– Standard Dosing is Not Sufficient to Achieve Therapeutic Concentrations
8. Excluded versus included patients in a randomized controlled trial of infections caused by carbapenem-resistant Gram-negative bacteria: relevance to external validity
9. A Pharmacometric Analysis of Patient-Reported Outcomes in Breast Cancer Patients Through Item Response Theory
10. Correction to: Model-Based Adaptive Optimal Design (MBAOD) Improves Combination Dose Finding Designs: an Example in Oncology
11. Model-based prediction of myelosuppression and recovery based on frequent neutrophil monitoring
12. A whole-body physiologically based pharmacokinetic (WB-PBPK) model of ciprofloxacin: a step towards predicting bacterial killing at sites of infection
13. Simulation-Based Evaluation of PK/PD Indices for Meropenem Across Patient Groups and Experimental Designs
14. Inter occasion variability in individual optimal design
15. A pharmacokinetic binding model for bevacizumab and VEGF165 in colorectal cancer patients
16. Performance of Nonlinear Mixed Effects Models in the Presence of Informative Dropout
17. Characterization of Endogenous G-CSF and the Inverse Correlation to Chemotherapy-Induced Neutropenia in Patients with Breast Cancer Using Population Modeling
18. A Mechanistic Pharmacokinetic Model Elucidating the Disposition of Trastuzumab Emtansine (T-DM1), an Antibody–Drug Conjugate (ADC) for Treatment of Metastatic Breast Cancer
19. Erratum to: Warfarin dose prediction in children using pharmacometric bridging – comparison with published pharmacogenetic dosing algorithms
20. Predictions of In Vivo Prolactin Levels from In Vitro K i Values of D2 Receptor Antagonists Using an Agonist–Antagonist Interaction Model
21. Warfarin dose prediction in children using pharmacometric bridging—comparison with published pharmacogenetic dosing algorithms
22. Longitudinal infusion of a complex of insulin-like growth factor-I and IGF-binding protein-3 in five preterm infants: pharmacokinetics and short-term safety
23. A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer
24. Population pharmacokinetics of cytarabine, etoposide, and daunorubicin in the treatment for acute myeloid leukemia
25. The shape of the myelosuppression time profile is related to the probability of developing neutropenic fever in patients with docetaxel-induced grade IV neutropenia
26. A simultaneous analysis of the time-course of leukocytes and neutrophils following docetaxel administration using a semi-mechanistic myelosuppression model
27. Predictive ability of a semi-mechanistic model for neutropenia in the development of novel anti-cancer agents: two case studies
28. Scaling the time-course of myelosuppression from rats to patients with a semi-physiological model
29. Limited inter-occasion variability in relation to inter-individual variability in chemotherapy-induced myelosuppression
30. Developmental Pharmacokinetics of Gentamicin in Preterm and Term Neonates
31. A Pharmacokinetic and Dosing Study of Intravenous Insulin-Like Growth Factor-I and IGF-Binding Protein-3 Complex to Preterm Infants
32. Application of pharmacokinetic-pharmacodynamic modeling in management of QT abnormalities after citalopram overdose. Reply to A. Manini
33. Reply to Dr. Mégarbane et al. regarding “Pharmacokinetic/pharmacodynamic modelling of cardiac toxicity in venlafaxine overdose”
34. Application of pharmacokinetic-pharmacodynamic modelling in management of QT abnormalities after citalopram overdose
35. Population Pharmacokinetics of Itraconazole and its Active Metabolite Hydroxy-Itraconazole in Paediatric Cystic Fibrosis and Bone Marrow Transplant Patients
36. The Population Pharmacokinetics of Citalopram After Deliberate Self-Poisoning: A Bayesian Approach
37. Mechanistic Models for Myelosuppression
38. Determination of drug effect on tumour cells, host animal toxicity and drug pharmacokinetics in a hollow-fibre model in rats
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.